A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer

Cancer: Lung
Study Phase: phase 3
Status: recruiting
Sponsor: Zai Lab (Shanghai) Co., Ltd. / Zai Lab (US) LLC
ClinicalTrials.gov Identifier: NCT07218146
Disease Focus: Small-cell Lung Cancer
Principal Investigator: Jun Zhang MD PhD
Clinical Research Coordinator: Vishnu Jaisree Mohandas MBBS MPH

Study Overview

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

clinicaltrials.gov NCT:NCT07218146

Interested in Participating in this Trial?

If you are interested in participating in this study, call the OSF Hope line at (844) 673- 4467 or email: sfmc.clinicaltrials@osfhealthcare.org